{"id":15646,"date":"2012-10-24T02:30:00","date_gmt":"2012-10-24T00:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/palmisano-italia-nel-gotha-della-ricerca-ma-pochi-brevetti\/"},"modified":"2012-10-24T02:30:00","modified_gmt":"2012-10-24T00:30:00","slug":"palmisano-italia-nel-gotha-della-ricerca-ma-pochi-brevetti","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/palmisano-italia-nel-gotha-della-ricerca-ma-pochi-brevetti\/","title":{"rendered":"Palmisano, Italy in the elite of research but few patents"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">Italy is an excellence in research: today it is in eighth place in the world for the quality of scientific publications measured through the impact factor. We are in the biotech elite. But we &#039;fall&#039; in the transition from the publication of studies to the realization of patents: in 2011 we filed 109, France 390, Germany 922. A ratio of 1 to 3 and even 1 to 9&quot;. <\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">This was underlined by Riccardo Palmisano, vice president of Assobiotec, participating in the 3rd Health Summit in Italy in Rome. &quot;The answer to the title of this round table, namely &#039;Healthcare as a driver of growth and development: a possible goal?&#039; \u2013 he underlined \u2013 is that yes, this is not only a possible goal, but a dutiful and unmissable one.Biotech, for example, brings 5 workers to related industries for each direct worker, against an average of 1-1.5 for the rest of the Italian manufacturing industry.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">Yet development plans for biotechnologies are not seen. It is often repeated - added Palmisano - that the 50% of the drugs that will arrive on the market will be biotech, but in half of the cases they are the result of collaboration with universities or spin-offs. The world of research has changed, we must seize the opportunities it offers us by boosting incentives, for which today Italy is in last place among the 8 main European countries. One example above all: a company has informed us that in Italy in 2009-2010 it obtained a tax credit of 1.6 million euros, in France of 16 million. <\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">There is room for biotech to leverage the excellence of Italian research and productivity - he concluded - but we need a system that provides incentives to invest, to ensure that small Italian businesses do not die before they have grown&quot;.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt; background: white; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><i style=\"mso-bidi-font-style: normal\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #333333; font-size: 9pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\">Barbara Di Chiara \u2013 October 24, 2012 \u2013 PharmaKronos<\/p>\n<p><\/span><\/i><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 10pt\"><span style=\"line-height: 115%; font-size: 9pt\"><\/p>\n<p><font face=\"Calibri\">&nbsp;<\/font><\/p>\n<p><\/span><\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>L&#8217;Italia &egrave; un&#8217;eccellenza nella ricerca: oggi &egrave; all&#8217;ottavo posto al mondo per qualit&agrave; delle pubblicazioni scientifiche misurata attraverso l&#8217;impact factor. Siamo nel gotha del biotech. Ma &#8216;cadiamo&#8217; nel passaggio dalla pubblicazione degli studi alla realizzazione dei brevetti: nel 2011 ne abbiamo depositati 109, la Francia 390, la Germania 922. Un rapporto di 1 a 3 &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15646","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15646"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15646\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}